Facial Paralysis Market Research Report – Forecast to 2027

Facial Paralysis Market Information: By Type (Bell’s Palsy, Ramsay Hunt Syndrome), by Diagnosis (Electromyography, Computerized Tomography), by Treatment (Medications, Physical Therapy), End-User (Hospitals, Specialty Centers)- Forecast Till 2027

ID: MRFR/MED/4486-HCR | October 2022 | Region: Global | 100 Pages         

Facial Paralysis Market

Facial Paralysis Market is expected to register a CAGR of 7.8% to reach USD 161.90 Million by 2030.

Segmentation

By Type Bell’s Palsy Ramsay Hunt Syndrome
by Diagnosis Electromyography Computerized Tomography
by Treatment Medications Physical Therapy
By End-User Hospitals Specialty Centers

Key Players

  • Boston Scientific
  • BioControl Medical
  • Cerebomed
  • Cyberonics
  • Astellas Pharma Inc.
  • Sucampo Pharmaceuticals
  • Novartis AG

Drivers

  • Increasing rate of strokes
Speak to Analyst Request a Free Sample

Facial Paralysis Market Overview


Facial Paralysis market is expected to grow at a CAGR of 6.5% during the forecast period. Face paralysis occurs when the muscles that control facial expressions are paralyzed. Drooping eyelids, inability to smile or frown, taste loss, hyperacusis, and decreased salivation and tear flow. Unilateral facial weakness is a common symptom of facial nerve paralysis. There are various options for treating facial paralysis including focusing on rehabilitation rather than surgery to reconnect nerve terminals. Patients may require artificial gadgets to regain their capacity to move their faces in some circumstances.


The high frequency of cardiovascular disorders, the introduction of technologically improved technologies, rising inflammation rates, rising stroke rates, and increasing market penetration are all driving the global facial paralysis market. Additionally, the market is expected to be driven by factors such as rising approvals for facial paralysis, government initiatives and assistance, and expanding reimbursement coverage for cardiologic anomalies. The rise in cases of facial paralysis is expected to be fueled by rising cardiovascular rates.


Figure: Global Facial Paralysis Market, by Region, 2017 (%)


 Facial Paralysis Market


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


Facial Paralysis Market Segments  


The global facial paralysis market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into bell’s palsy, Ramsay Hunt syndrome, and Lyme disease.


On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.


 On the basis of treatment, the market is segmented into medications, physical therapy,


On the basis of medications, the market is further sub-segmented into corticosteroids and antiviral drugs. 


On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.


Facial Paralysis Market Regional Analysis


The North American facial paralysis market is a growing market in the Americas region. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing cardiovascular rate is likely to enhance the growth of facial paralysis. Additionally, the increasing demand for minimally invasive procedures, rising government support, and rising demand for technologically advanced treatments are likely to enhance the growth of the facial paralysis market in North America. For instance, according to the American Heart Association, 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, in 2015, around USD 3.2 trillion were spend in healthcare expenditure in the U.S according to the Center for Disease Control and Prevention.


Europe is the second largest market and holds a healthy share in the global facial paralysis market. The European market is expected to grow a during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing need for better healthcare infrastructure. Furthermore, the increasing cardiovascular rate along with the rising population inclined towards the sedentary lifestyle is driving the growth of the facial paralysis market. According to the European Heart Network, in 2015, there were 11.3 million cardiovascular disorder cases in Europe.


Asia Pacific is expected to be the fastest growing market owing to the increasing prevalence of cardiovascular disorders and increasing inflammation rates. China is the fastest growing region owing to an increasing population. The increasing awareness about the health and availability of new treatment methods drives the market in this region. Increasing healthcare expenditure and rise in the standard of living are driving the growth of the facial paralysis market in the Asia Pacific region.


The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and increasing availability of specialty care centers.


Key Players       


Some of the key players in the facial paralysis market are Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.

Recent Development


Ultomiris from AstraZeneca achieves primary endpoint in PhIII NMOSD study. Ultomiris (ravulizumab-cwvz), a long-acting C5 complement inhibitor, met its primary endpoint in the Phase III CHAMPION-NMOSD investigation, according to this UK pharma. The goal was to prove a "statistically significant and clinically meaningful reduction in the probability of relapse in individuals" with a rare autoimmune illness that affects the central nervous system.


Horizon Therapeutics plc's (HZNP) Uplizna or inebilizumab has been authorized by the European Commission for the treatment of adults with Neuromyelitis Optica Spectrum Disorder. Uplizna is a monotherapy for adult patients with Neuromyelitis Optica Spectrum Disorder who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+), which accounts for about 80% of Neuromyelitis Optica Spectrum Disorder cases. Neuromyelitis Optica Spectrum Disorder is a life-threatening autoimmune disease characterized by severe and frequent attacks on the central nervous system that can cause blindness, paralysis, and death.


Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology


 Facial Paralysis Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis


 



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Facial paralysis is a restriction of facial muscles due to nerve damage.

Global Facial Paralysis Market is expected to exhibit a strong 6.5% CAGR over the forecast period from 2018 to 2023.

The increasing rate of stroke is likely to be a major driver for the Facial Paralysis Market.

The Americas hold a dominant 48% share in the global Facial Paralysis Market.

Leading players in the Facial Paralysis Market include Boston Scientific, Cerebomed, and Astellas Pharma, among others.